• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Stock Biotech’s Big Comeback: Why Investors are Eyeing This Beaten-Down Sector
Stock

Biotech’s Big Comeback: Why Investors are Eyeing This Beaten-Down Sector

by September 10, 2024
by September 10, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

Perhaps no other industry in the world is more synonymous with risk and emergent (R&D) developments like biotechnology. While the information technology sector has been a dominant driver on Wall Street since the big tech revolution in the 2000s, biotech, a subset of the healthcare sector, took a sharp nosedive during the pandemic in 2020.

By 2020, 80% of all biotech companies were losing money. Near-zero interest rates made it easy for biotech companies to continue raising capital to fund their operations. But as the Fed began raising interest rates a few years later to combat rising inflation, the capital lifeline was cut, and the biotech industry cratered.

But now, with Fed rate cuts on the horizon, Wall Street may be eying this beaten-down industry, currently trading with bargain basement valuations. Does this present an opportunity for a long trade?

Biotech vs. the Broader Healthcare Sector

Let’s look at biotech starting at its 2020 top and compare it to the broader healthcare sector. We’ll use the following industry and sector proxies:

SPDR S&P Biotech ETF (XBI) for our biotech industry proxyHealth Care Select Sector SPDR Fund (XLV) for our sector proxy

Go to your StockCharts Dashboard and open up PerfCharts. Type in XBI,XLV and drag the bottom timeline slider to around 932 days. It should look like this:

CHART 1. PERFCHART OF XBI AND XLV. The chart starts when XBI hit a top in 2020.Chart source: StockCharts.com. For educational purposes.

To get an idea of relative performance, this shows you just how much the biotech proxy has been underperforming healthcare over the last three years.

With that knowledge, what’s going on today with regard to biotech relative to its sector? Why not get a quick glance at the Advancers & Decliners?

In one of the data panels on your StockCharts dashboard, select the More button and click Advancers & Decliners > US Sectors. On Tuesday (mid-day), this is what I saw:

CHART 2. ADVANCERS & DECLINERS BY SECTOR. Notice that the number of advancing and declining stocks are neck-and-neck.Image source: StockCharts.com. For educational purposes.

This tells me something about healthcare as a sector—namely, that the number of stocks going up and down is nearly the same. But it doesn’t tell me much about biotech as an industry.

So, let’s check the StockCharts Sector Summary and drill down.

Open the page and click on XLV. You should see each individual industry. Let’s select a three-month look-back to get a bigger picture of industry performance. This is what I got:

CHART 3. 3-MONTH INDUSTRY VIEW ON STOCKCHARTS’ SECTOR SUMMARY. Biotech rising?Image source: StockCharts.com. For educational purposes.

This tells you that, over the last quarter, biotech’s market performance has been second only to healthcare providers. But take a look at the volume. It has the highest volume of trades in the entire sector. Could this mean that Wall Street is steadily accumulating biotech stocks, fueling its rise to date? If so, is biotech on the verge of an upside trend reversal?

 Let’s look at a daily chart of XBI to see what the price action says.

CHART 4. DAILY CHART OF XBI. There’s a very wide ascending triangle formation in the price chart; the stochastic oscillator is starting to turn higher above the 20 level, and On Balance Volume is trending higher.Chart source: StockCharts.com. For educational purposes.

Here are the main points to watch:

XBI has been trending upward since late April, and it’s about to challenge the $103 range (see blue dotted line) marking the March 2023 high and this year’s July and August highs, forming a long ascending triangle pattern which leans on the bullish side.Price appears to be bouncing off the stochastic oscillator’s 20 line (see orange circle), just above oversold territory.The On Balance Volume (OBV) indicator, whose founding principle is “volume precedes price,” shows that buying pressure is on a steady uptrend, mirroring XBI’s price action.

For XBI’s uptrend to remain valid and to see if Wall Street capital begins flowing into biotech ahead of the anticipated Fed rate cuts, XBI will have to break through resistance at the $103 range while staying above the current trend line (see solid blue trendline) or the last major swing low at $91.

At the Close

Here’s the takeaway: Biotech has had it rough since its 2020 peak, but there could be some light at the end of the tunnel. With Fed rate cuts on the horizon, Wall Street might be eyeing this beaten-down industry for a rebound. Keep an eye on the technical levels to spot any hint of major market moves before the rest of the crowd catches on.

Last but not least, be sure to save XBI in one of your StockCharts ChartLists.

Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

You Might Also Like
  • Cybersecurity Makes Yet Another Statement
  • Which Sectors Benefit Most From the Large- to Mid- & Small-Cap Rotation?
  • This S&P 500 Rally is Defying the Experts – Here’s What You Need to Know
  • LUV Stock: Will Tailwinds Make the Stock Soar?
Share
0
FacebookTwitterPinterestWhatsapp

previous post
New Starbucks CEO Brian Niccol outlines priorities to end coffee chain’s slump
next post
Stock Market Today: Real Estate and Tech Lead, Energy Down

You may also like

Sector Spotlight: Money Rotating Out of Large-Cap Growth Stocks

August 14, 2023

Upgrade Your Options Trading with OptionsPlay on StockCharts

November 14, 2024

Find Great Trading Ideas By Combining SCTR Rankings and RRG

November 10, 2023

You Need To Realize ONE Important Fact With Big Rallies...

March 9, 2024

Looking for Strong Stocks to Buy? Start with These Three...

May 13, 2023

Master the MACD Zero Line for a Trading Edge!

December 11, 2024

Growth Stocks Seen THRIVING in Anticipation of NVDA Earnings

August 23, 2023

DecisionPoint Trading Room: Narrow Advance a Big Problem!

February 5, 2024

Stock Market Wrap: Stocks Rebound as May Kicks Off with...

May 2, 2025

Time to Talk 6-7 Year Market Business Cycles

October 4, 2023

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

      May 8, 2025
    • Don’t Buy Robinhood Stock… Until You See This Chart Setup

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025
    • The Unpredictable Stock Market: How to Make Sense of It

      May 8, 2025
    • AMD CEO calls China a ‘large opportunity’ and warns against strict U.S. chip controls

      May 7, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,630 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,339 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,320 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,302 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,186 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,066)
    • Investing (538)
    • Stock (2,530)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout,...

      May 8, 2025
    • Don’t Buy Robinhood Stock… Until You See This Chart Setup

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,066)
    • Investing (538)
    • Stock (2,530)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Nasdaq/NYSE Volume Ratio Says No Price...

    March 9, 2023

    Will the S&P 500 Break 5000...

    July 27, 2024

    The Ord Oracle August 22, 2023

    August 23, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here